




NEW TAILORED MEDICINE IN METASTASIC MELANOMA

TEST COMPANION AND RNA-TARGETED DRUG



TSB-CTR
SKMel28 Xenograft



INNOVATIVE OPPORTUNITY

Context: Metastatic Melanoma is one of the most aggressive form of skin cancer. Combination of targeted therapies or immune checkpoint therapies have increased the Overall Survival (OS) of patients with metastatic Melanoma (MM). Presently, on going trials consider the use of tri-therapies to extend the time of patient OS. Adjuvant therapies are also under investigation.

Issue:

- Propose a new class of therapy: RNA-targeted therapy to the 'non-responders' or 'resistants'
- Increase the duration of the survival of patients with metastatic melanoma.
- Propose a new target for other types of melanoma (uveal, mucosal)

Solution: Scientists have identified a highly expressed mRNA that dampens the tumor suppressor activity of a miRNA. They propose to restore the activity of this 'natural brake' by avoiding miRNA sequestration. They use with success very specific Target Site Blockers (TSB, 16 modified nucleotides single strand).

The offer includes:

- a companion test to predict the miRNA sequestration: 3 parameters are tested (one SNP and the expression level of two mRNA).
- A RNA-targeted therapy: TSB are injected subcutaneously, vectorization is not required. They restore the tumor suppressor activity of a given miRNA in melanoma cells and consequently abolish cell proliferation.

Mutation:	BRAF	NRAS	TP53
501Mel			
MM001			
Me1402			
MM087			
MM057			
MM165			

Gilot, Migault ... Galibert. *Nature Cell Biology* Nov. 2017

POTENTIAL APPLICATIONS

Oncology:

- Metastatic Melanoma
- 2nd / 3rd line
- Combination
- Other types of melanoma : uveal melanoma – mucosal melanoma
- TYRPI- expressing cancer

BENEFITS

- Combination with targeted and immune checkpoint therapies possible
- Independent of BRAF/ NRAS mutations
- Natural mechanism – low resistance expected
- No side effect *in vivo* (mice)

INTELLECTUAL PROPERTY STATUS

- Priority date 06/11/2013
- US , CA , EP extensions
- Published WO2015067710

DEVELOPPEMENT STATUS

- *In vitro* tests : Short-term melanoma cultures & melanoma cell lines : efficiency up to 83% (cytostatic and cytotoxic activities)
- *In vivo* tests :
 - Melanoma cell Xenograft
 - Patient-Derived Xenograft model (BRAF V600E) – 12 days.

LABORATORIES

- Prof. Marie-Dominique Galibert
- David Gilot (PhD)
- Labs: UMR 6290 CNRS - IGDR

CONTACT
SATT Ouest Valorisation
 14 C Rue du Patis Tatelin
 Rennes, France
 Phone: 00 33 299875600
 Mail: info@ouest-valorisation.fr